263 related articles for article (PubMed ID: 30726562)
1. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L;
Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562
[TBL] [Abstract][Full Text] [Related]
2. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
3. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Merli M; Rattotti S; Spina M; Re F; Motta M; Piazza F; Orsucci L; Ferreri AJM; Perbellini O; Dodero A; Vallisa D; Pulsoni A; Santoro A; Sacchi P; Zuccaro V; Chimienti E; Russo F; Visco C; Zignego AL; Marcheselli L; Passamonti F; Luminari S; Paulli M; Bruno R; Arcaini L;
J Clin Oncol; 2022 Dec; 40(35):4060-4070. PubMed ID: 35714311
[TBL] [Abstract][Full Text] [Related]
4. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.
Arcaini L; Besson C; Frigeni M; Fontaine H; Goldaniga M; Casato M; Visentini M; Torres HA; Loustaud-Ratti V; Peveling-Oberhag J; Fabris P; Rossotti R; Zaja F; Rigacci L; Rattotti S; Bruno R; Merli M; Dorival C; Alric L; Jaccard A; Pol S; Carrat F; Ferretti VV; Visco C; Hermine O
Blood; 2016 Nov; 128(21):2527-2532. PubMed ID: 27605512
[TBL] [Abstract][Full Text] [Related]
5. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization.
Torres HA; Mahale P
Liver Int; 2015 Jun; 35(6):1661-4. PubMed ID: 25779000
[TBL] [Abstract][Full Text] [Related]
6. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
Michot JM; Canioni D; Driss H; Alric L; Cacoub P; Suarez F; Sibon D; Thieblemont C; Dupuis J; Terrier B; Feray C; Tilly H; Pol S; Leblond V; Settegrana C; Rabiega P; Barthe Y; Hendel-Chavez H; Nguyen-Khac F; Merle-Béral H; Berger F; Molina T; Charlotte F; Carrat F; Davi F; Hermine O; Besson C;
Am J Hematol; 2015 Mar; 90(3):197-203. PubMed ID: 25417909
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Virus-Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment.
Pozzato G; Mazzaro C; Gattei V
Clin Liver Dis; 2017 Aug; 21(3):499-515. PubMed ID: 28689589
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.
Persico M; Aglitti A; Caruso R; De Renzo A; Selleri C; Califano C; Abenavoli L; Federico A; Masarone M
Hepatology; 2018 Jan; 67(1):48-55. PubMed ID: 28714143
[TBL] [Abstract][Full Text] [Related]
9. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.
Hosry J; Mahale P; Turturro F; Miranda RN; Economides MP; Granwehr BP; Torres HA
Int J Cancer; 2016 Dec; 139(11):2519-28. PubMed ID: 27501007
[TBL] [Abstract][Full Text] [Related]
10. In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas.
Canioni D; Michot JM; Rabiega P; Molina TJ; Charlotte F; Lazure T; Davi F; Settegrana C; Berger F; Alric L; Cacoub P; Terrier B; Suarez F; Sibon D; Dupuis J; Feray C; Tilly H; Pol S; Deau Fischer B; Roulland S; Thieblemont C; Leblond V; Carrat F; Hermine O; Besson C;
PLoS One; 2016; 11(6):e0156384. PubMed ID: 27257992
[TBL] [Abstract][Full Text] [Related]
11. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
[TBL] [Abstract][Full Text] [Related]
12. miRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon-free antiviral therapy.
Peveling-Oberhag J; Bankov K; Dultz G; Ballo O; Lohmeyer J; Brunnberg U; Marcu V; Walter D; Zeuzem S; Hansmann ML; Welzel TM; Vermehren J
Antivir Ther; 2019; 24(6):437-442. PubMed ID: 31180334
[TBL] [Abstract][Full Text] [Related]
13. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
Peveling-Oberhag J; Arcaini L; Bankov K; Zeuzem S; Herrmann E
J Viral Hepat; 2016 Jul; 23(7):536-44. PubMed ID: 26924533
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.
Merli M; Carli G; Arcaini L; Visco C
World J Gastroenterol; 2016 Oct; 22(38):8447-8458. PubMed ID: 27784957
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management.
Peveling-Oberhag J; Arcaini L; Hansmann ML; Zeuzem S
J Hepatol; 2013 Jul; 59(1):169-77. PubMed ID: 23542089
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy.
Mazzaro C; Bomben R; Gragnani L; Visentini M; Pozzato G; Pozzo F; Zucchetto A; Gattei V
Semin Hematol; 2022 Oct; 59(4):177-182. PubMed ID: 36805885
[TBL] [Abstract][Full Text] [Related]
17. Elbasvir/Grazoprevir combination therapy in a B-NHL patient with HCV genotype 1 infection.
Sica A; Spada A; Sagnelli C; Verolino P; Mazzocca A; Sagnelli E; Colella G; Guastafierro S; Marrone A
Infez Med; 2021 Jun; 29(2):277-279. PubMed ID: 34061795
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland.
Zucca E; Roggero E; Maggi-Solcà N; Conconi A; Bertoni F; Reilly I; Castelli D; Pedrinis E; Piffaretti JC; Cavalli F
Haematologica; 2000 Feb; 85(2):147-53. PubMed ID: 10681721
[TBL] [Abstract][Full Text] [Related]
19. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
20. Antiviral therapies for managing viral hepatitis in lymphoma patients.
Merli M; Rattotti S; Gotti M; Arcaini L
Expert Opin Pharmacother; 2017 Mar; 18(4):363-376. PubMed ID: 28140702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
